• Email:sales@AmericanPharmaWholesale.com
  • Site Map




Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#, UPC# or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.


Menu

RX ITEM-Retacrit epoetin alfa-epbx INJ VIAL 40K 40000/ML vial 4X1Ml by Pfizer

Retacrit epoetin alfa-epbx INJ VIAL 40K 40000/ML vial 4X1Ml by Pfizer.  Item No.:RX755249 755249  NDC No. 00069-1309-04 0069-1309-04 0069130904 00069130904 69130904   UPC: 3-00691-30904-6 300691309046Retacrit epoetin alfa-epbx INJECTION VIAL 2000/ML vial 10X1Ml by Pfizer Item No.:RX755231 755231 NDC No. 69130510 00069-1305-10 0069-1305-10 0069130510 00069130510  UPC No.:3-00691-30510-9  3006913051Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scopWant to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.Retacrit epoetin alfa-epbx INJECTION VIAL 2000/ML vial 10X1Ml by Pfizer Item No.:RX755231 755231 NDC No. 69130510 00069-1305-10 0069-1305-10 0069130510 00069130510  UPC No.:3-00691-30510-9  3006913051Retacrit epoetin alfa-epbx INJ VIAL 40K 40000/ML vial 4X1Ml by Pfizer.  Item No.:RX755249 755249  NDC No. 00069-1309-04 0069-1309-04 0069130904 00069130904 69130904   UPC: 3-00691-30904-6 300691309046RETACRIT 3000 UN/ML VL 10X1ML
epoetin alfa-epbx INJECTION VIAL 3000/MLItem No.:RX755241 755241  NDC No. 69130710 00069-1307-10 0069-1307-10 0069130710 00069130710  UPC: 3-00691-30713 300691-307103 300691307103 MPN 130710

RX ITEM-Retacrit epoetin alfa-epbx INJ VIAL 40K 40000/ML vial 4X1Ml by Pfizer

$2117.76$1849.00

Item No.:RX755249 755249 NDC No. 00069-1309-04 0069-1309-04 0069130904 00069130904 69130904 UPC: 3-00691-30904-6 300691309046 300691-309046 MPN 130904
EPOETIN ALFA , see Procrit, Epogen BY PFIZER
Description:
RETACRIT SF 40000U/ML 4X1ML vials

Strength:
3000U/ML
Form:
SINGLEDOSE PRESRV FREE VIAL
Size:
10X1 ML Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacis

Have a question?

These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT� (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar * to EPOGEN/PROCRIT (epoetin alfa) WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE See full prescribing information for complete boxed warning. Chronic Kidney Disease: In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (5.1). No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest RETACRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions (5.1). Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (5.2). Use the lowest dose to avoid RBC transfusions (2.4). Use ESAs only for anemia from myelosuppressive chemotherapy (1.3). ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.5). Discontinue following the completion of a chemotherapy course (2.4). Perisurgery: Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended (5.1). INDICATIONS AND USAGE RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis (1.1). Zidovudine in patients with HIV-infection (1.2). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy (1.3). Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery (1.4). Limitations of Use RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being (1.5). RETACRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy (1.5). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure (1.5). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion (1.5). In patients scheduled for surgery who are willing to donate autologous blood (1.5). In patients undergoing cardiac or vascular surgery (1.5). As a substitute for RBC transfusions in patients who require immediate correction of anemia (1.5). DOSAGE AND ADMINISTRATION Evaluate iron status before and during treatment and maintain iron repletion. Correct or exclude other causes of anemia before initiating treatment (2.1). Patients with CKD: Initial dose: 50 to 100 Units/kg 3 times weekly (adults) and 50 Units/kg 3 times weekly (pediatric patients). Individualize maintenance dose. Intravenous route recommended for patients on hemodialysis (2.2). Patients on Zidovudine due to HIV-infection: 100 Units/kg 3 times weekly (2.3). Patients with Cancer on Chemotherapy: 40,000 Units weekly or 150 Units/kg 3 times weekly (adults); 600 Units/kg intravenously weekly (pediatric patients ? 5 years) (2.4). Surgery Patients: 300 Units/kg per day daily for 15 days or 600 Units/kg weekly (2.5). DOSAGE FORMS AND STRENGTHS Injection 2,000 Units/mL, 3,000 Units/mL, 4,000 Units/mL, 10,000 Units/mL, and 40,000 Units/mL in single-dose vials (3) CONTRAINDICATIONS Uncontrolled hypertension (4) Pure red cell aplasia (PRCA) that begins after treatment with RETACRIT or other erythropoietin protein drugs (4) Serious allergic reactions to RETACRIT or other epoetin alfa products (4) WARNINGS AND PRECAUTIONS Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism: Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit (5.1 and 14.1). Use caution in patients with coexistent cardiovascular disease and stroke (5.1). Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients With Cancer (5.2). Hypertension: Control hypertension prior to initiating and during treatment with RETACRIT (5.3). Seizures: epoetin alfa products increase the risk for seizures in patients with CKD (5.4). Increase monitoring of these patients for changes in seizure frequency or premonitory symptoms (5.4). PRCA: If severe anemia and low reticulocyte count develop during RETACRIT treatment, withhold RETACRIT and evaluate for PRCA (5.6). Serious Allergic Reactions: Discontinue RETACRIT and manage reactions (5.7). Severe Cutaneous Reactions: Discontinue RETACRIT (5.8). Phenylketonurics: Contains phenylalanine (5.9). ADVERSE REACTIONS Patients with CKD: Adverse reactions in ? 5% of epoetin alfa-treated patients in clinical studies were hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, and upper respiratory tract infection (6.1). Patients on Zidovudine due to HIV-infection: Adverse reactions in ? 5% of epoetin alfa-treated patients in clinical studies were pyrexia, cough, rash, and injection site irritation (6.1). Patients with Cancer on Chemotherapy: Adverse reactions in ? 5% of epoetin alfa-treated patients in clinical studies were nausea, vomiting, myalgia, arthralgia, stomatitis, cough, weight decrease, leukopenia, bone pain, rash, hyperglycemia, insomnia, headache, depression, dysphagia, hypokalemia, and thrombosis (6.1). Surgery Patients: Adverse reactions in ? 5% of epoetin alfa-treated patients in clinical studies were nausea, vomiting, pruritus, headache, injection site pain, chills, deep vein thrombosis, cough, and hypertension (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc., a Pfizer company, at 1-800-438-1985, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. * Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of RETACRIT has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. Revised: 5/2018

Retacrit epoetin alfa-epbx INJ VIAL 40K 40000/ML vial 4X1Ml by Pfizer.  Item No.:RX755249 755249  NDC No. 00069-1309-04 0069-1309-04 0069130904 00069130904 69130904   UPC: 3-00691-30904-6 300691309046
Retacrit epoetin alfa-epbx INJ
Retacrit epoetin alfa-epbx INJ VIAL 40K 40000/ML vial 4X1Ml by Pfizer. Item No.:RX755249 755249 NDC No. 00069-1309-04 0069-1309-04 0069130904 00069130904 69130904 UPC: 3-00691-30904-6 300691309046

Retacrit epoetin alfa-epbx INJECTION VIAL 2000/ML vial 10X1Ml by Pfizer Item No.:RX755231 755231 NDC No. 69130510 00069-1305-10 0069-1305-10 0069130510 00069130510  UPC No.:3-00691-30510-9  3006913051
Retacrit epoetin alfa-epbx INJ
Retacrit epoetin alfa-epbx INJECTION VIAL 2000/ML vial 10X1Ml by Pfizer Item No.:RX755231 755231 NDC No. 69130510 00069-1305-10 0069-1305-10 0069130510 00069130510 UPC No.:3-00691-30510-9 3006913051

Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop
American Pharma Wholesale
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

Retacrit epoetin alfa-epbx INJECTION VIAL 2000/ML vial 10X1Ml by Pfizer Item No.:RX755231 755231 NDC No. 69130510 00069-1305-10 0069-1305-10 0069130510 00069130510  UPC No.:3-00691-30510-9  3006913051
Retacrit epoetin alfa-epbx INJ
Retacrit epoetin alfa-epbx INJECTION VIAL 2000/ML vial 10X1Ml by Pfizer Item No.:RX755231 755231 NDC No. 69130510 00069-1305-10 0069-1305-10 0069130510 00069130510 UPC No.:3-00691-30510-9 3006913051

Retacrit epoetin alfa-epbx INJ VIAL 40K 40000/ML vial 4X1Ml by Pfizer.  Item No.:RX755249 755249  NDC No. 00069-1309-04 0069-1309-04 0069130904 00069130904 69130904   UPC: 3-00691-30904-6 300691309046
Retacrit epoetin alfa-epbx INJ
Retacrit epoetin alfa-epbx INJ VIAL 40K 40000/ML vial 4X1Ml by Pfizer. Item No.:RX755249 755249 NDC No. 00069-1309-04 0069-1309-04 0069130904 00069130904 69130904 UPC: 3-00691-30904-6 300691309046

RETACRIT 3000 UN/ML VL 10X1ML
epoetin alfa-epbx INJECTION VIAL 3000/ML
RETACRIT 3000 UN/ML VL 10X1ML
RETACRIT 3000 UN/ML VL 10X1ML epoetin alfa-epbx INJECTION VIAL 3000/ML

Item No.:RX755241 755241  NDC No. 69130710 00069-1307-10 0069-1307-10 0069130710 00069130710  UPC: 3-00691-30713 300691-307103 300691307103 MPN 130710
Retacrit epoetin alfa-epbx INJ
Item No.:RX755241 755241 NDC No. 69130710 00069-1307-10 0069-1307-10 0069130710 00069130710 UPC: 3-00691-30713 300691-307103 300691307103 MPN 130710